



HAL
open science

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer's disease and other proteinopathies

Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz, Sylvain Lehmann

► **To cite this version:**

Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz, Sylvain Lehmann. Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer's disease and other proteinopathies. *Alzheimer's Research and Therapy*, 2023, 15 (1), pp.170. 10.1186/s13195-023-01318-2. hal-04649689

HAL Id: hal-04649689

<https://hal.science/hal-04649689>

Submitted on 16 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

MINI REVIEW

Open Access



Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer's disease and other proteinopathies

Pablo Mohaupt¹, Jérôme Vialaret¹, Christophe Hirtz^{1*} and Sylvain Lehmann¹

Abstract

The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous interchange between cerebrospinal fluid and brain interstitial fluid by convective flow movement. This flow is responsible for guiding proteins and metabolites away from the CNS. Proteinopathies are neurological conditions characterized by the accumulation of aggregated proteins or peptides in the brain. In Alzheimer's disease (AD), the deposition of amyloid- β (A β) peptides causes the formation of senile plaques. This accumulation has been hypothesized to be a result of the imbalance between A β production and clearance. Recent studies have shown that an extended form of AQP4 increases A β clearance from the brain. In this mini-review, we present a summary of these findings and explore the potential for future therapeutic strategies aiming to boost waste clearance in AD.

Keywords Aquaporin-4, Waste clearance, Proteinopathies, Alzheimer's, Protein aggregation, Therapeutic target

Background

Translation is a critical biological process that entails the conversion of genetic information encoded in messenger RNA (mRNA) into functional proteins. Traditionally, eukaryotic mRNA was thought to be inherently monocistronic, denoting that each mRNA molecule codes for a single protein sequence. Recent advances in ribosome sequencing and proteomics research have challenged the traditional view of protein translation, revealing a more complex translational landscape [1–4]. It is notable that assumptions regarding protein translation are deeply ingrained in proteomics research, as protein databases are built upon these assumptions and do not encompass the entirety of the human proteome. We recently

reviewed microproteins and dual-coding properties of mRNA in neurobiology and their potential involvement in neurodegenerative disorders [5]. For example, transcripts coding for prion protein (PrP), A2A adenosine receptor (A2AR), ataxin-1, and FUS encode an additional protein besides the reference protein [6–9]. Notably, the alternatively translated proteins can serve distinct functions. For instance, two proteins translated from the same FUS mRNA have distinct functions but also both contribute to FUS-mediated motor neuron toxicity [9]. The aforementioned proteins have distinct amino acid sequences due to translation in a different reading frame or in untranslated regions of mRNA. A better-known phenomenon of diversity at the protein level is protein isoforms. Protein isoforms are typically defined as proteins translated from alternatively spliced transcripts. However, shorter or longer versions of a protein with distinct functionality can also be translated from the same transcript. For instance, a shorter version of the protein peripherin is co-expressed with the reference protein,

*Correspondence:

Christophe Hirtz
christophe.hirtz@umontpellier.fr

¹ LBPC-PPC, Université de Montpellier, IRMB CHU de Montpellier, INM INSERM, Montpellier, France



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

due to in-frame translation initiation occurring downstream of the presumed start codon [10]. This isoform is involved in the process of filament network formation. Recent studies describe the discovery of an extended version of the protein aquaporin-4 (AQP4X), expressed in rat, mice, and human [11, 12]. The translation initiation occurs at the same start codon as the reference protein aquaporin-4 (AQP4), but in some occasions, the elongation does not stop at the stop codon resulting in an extended version of the protein. Hence, this isoform is not formed due to polycistronic features of the DNA or mRNA but due to regulatory aspects of protein translation.

Amyloid-beta clearance via the glymphatic system

Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) deposits and hyperphosphorylated tau tangles within the brain. To maintain brain homeostasis, various clearance systems exist to eliminate extracellular Aβ from the central nervous system, including the glymphatic pathway [13]. AQP4, which is located perivascular on astrocyte endfeet, plays a vital role in proper functioning of the glymphatic system (Fig. 1) [14].

Studies using infused radiolabeled Aβ₁₋₄₀ indicate that AQP4-knockout mice exhibit a 55% lower Aβ clearance

rate than wild-type mice [15]. Moreover, in an amyloid-beta precursor protein/presenilin 1 (APP/PS1) transgenic mouse model for AD, AQP4-knockout mice show a reduced Aβ clearance rate of 25–50% compared to transgenic mice without AQP4-knockout [16]. The AQP4 levels in cerebrospinal fluid are higher in neurodegenerative dementia, but the perivascular localization of AQP4, which is elemental to proper functioning of the glymphatic system, is disrupted in AD [17, 18]. Several studies indicate that the isoforms exhibit divergent subcellular localizations: the AQP4X isoform is predominantly associated with astrocytic endfeet proximate to vasculature, whereas the canonical AQP4 is situated in the parenchyma, distanced from the vascular structures [11, 12]. This suggests that the translation of the extended isoform could potentially improve waste clearance from the CNS. AQP4X is translated inherently, but the stoichiometry between AQP4 and AQP4X is disrupted in gliosis and, more specifically, the AQP4X/AQP4 ratio was found to be decreased in AD in APP/PS1 transgenic mice models [11, 19]. In an effort to increase the readthrough rate using apigenin and sulphaquinoxaline, and thus increase the translation of AQP4X, an increase in Aβ clearance was observed [19]. These findings suggest that promoting waste clearance could be a valuable tool for slowing




Fig. 1 Amyloid-beta clearance via the glymphatic system. Aquaporin-4 (AQP4) water channels facilitate the continuous interchange between cerebrospinal fluid and brain interstitial fluid by convective flow movement. These water channels are positioned on the endfeet of astrocytes situated at the outer layer of the artery and vein. The glymphatic flow guides proteins, such as amyloid-beta, and metabolites to the perivenous space via AQP4 water channels, thus promoting their efficient elimination from the central nervous system outside the brain

down disease progression in AD. Further research is necessary to determine the clinical potential of this approach in long term studies evaluating plaque formation and cognitive function. The application of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene-editing technology presents a potential alternative strategy for future implementation [20]. However, it should be noted that this approach may result in the complete cessation of the translation of canonical AQP4, while both isoforms might be required for maintaining brain health. Additionally, it would be valuable to evaluate if the clearance is specific for A β or if this strategy also has potential for other proteinopathies. For instance, α -synuclein build-up is associated with synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), but accumulating evidence also suggests its involvement in the pathophysiology of AD [21]. To evaluate this paradigm would particularly be of interest since the decreased expression of AQP4 in a PD mice model showed accelerated deposition of α -synuclein [22, 23].

Therapeutic strategies for AD, such as aducanumab and lecanemab, rely on antibodies that target A β or A β protofibrils. Furthermore, there has been recent interest in microglial activation as a therapeutic strategy to slow down A β accumulation and tau deposition [24]. A β -targeting antibodies have shown potential in neutralizing A β , suggesting a path for enhanced clearance. Once activated, microglia appear primed to efficiently phagocytose and degrade these antibody-tagged aggregates [25]. Enhancing waste clearance mechanisms, such as the glymphatic system, might not only slow the amyloid aggregation process but might also aid in the effective spread of antibodies within the brain tissue due to improved glymphatic flow. The potential synergy between waste clearance mechanisms and A β -targeting antibodies remains an intriguing avenue for future therapeutic strategies in AD.

Conclusions

The enhancement of waste clearance from the brain via the glymphatic system is a novel therapeutic approach for AD. While the definitive clinical implications of AQP4, AQP4X, and the glymphatic system are yet to be ascertained, this avenue suggests a potential direction for future therapeutic exploration. These findings also suggest that promoting waste clearance holds promise for slowing down protein accumulation in other proteinopathies.

Abbreviations

A2AR A2A Adenosine receptor

A β	Amyloid- β
AD	Alzheimer's disease
APP	Amyloid-beta precursor protein
AQP4	Aquaporin-4
AQP4X	Extended aquaporin-4
CNS	Central nervous system
CRISPR/Cas9	Clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9
DLB	Dementia with Lewy bodies
DNA	Deoxyribonucleic acid
mRNA	Messenger RNA
MSA	Multiple system atrophy
PD	Parkinson's disease
PrP	Prion protein
PS1	Presenilin 1

Acknowledgements

Not applicable

Authors' contributions

P.M. conceptually designed the work. P.M. wrote the manuscript. P.M. made the illustration. C.H. J.V. and S.L. reviewed the manuscript. All authors read and commented on the manuscript.

Funding

This project has received funding (support for PM and the laboratory) from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860197 MIRIADE.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The figure is original, created with BioRender.com.

Competing interests

The authors declare no competing interests.

Received: 30 March 2023 Accepted: 27 September 2023

Published online: 11 October 2023

References

- Vanderperre B, Lucier J-F, Bissonnette C, Motard J, Tremblay G, Vanderperre S, et al. Direct detection of alternative open reading frames translation products in human significantly expands the proteome. *PLoS One*. 2013;8:e70698.
- Menschaert G, Van Crielinge W, Notelaers T, Koch A, Crappé J, Gevaert K, et al. Deep proteome coverage based on ribosome profiling aids mass spectrometry-based protein and peptide discovery and provides evidence of alternative translation products and near-cognate translation initiation events*. *Mol Cell Proteomics*. 2013;12:1780–90.
- Ji Z, Song R, Regev A, Struhl K. Many lncRNAs, 5'UTRs, and pseudogenes are translated and some are likely to express functional proteins. *Sonenberg N, editor. Sonenberg N eLife*. 2015;4:e08890.
- Chen J, Brunner A-D, Cogan JZ, Nuñez JK, Fields AP, Adamson B, et al. Pervasive functional translation of non-canonical human open reading frames. *Science*. 2020;367:1140–6.
- Mohaupt P, Roucou X, Delaby C, Vialaret J, Lehmann S, Hirtz C. The alternative proteome in neurobiology. *Frontiers in Cellular Neuroscience*.

- 2022;16. Available from: <https://www.frontiersin.org/articles/10.3389/fncel.2022.1019680>. [Cited 2023 Mar 9]
6. Vanderperre B, Staskevicius AB, Tremblay G, McCoy M, O'Neill MA, Cashman NR, et al. An overlapping reading frame in the PRNP gene encodes a novel polypeptide distinct from the prion protein. *FASEB J*. 2011;25:2373–86.
 7. Lee C, Lai H-L, Lee Y-C, Chien C-L, Chern Y. The A2A adenosine receptor is a dual coding gene. *J Biol Chem*. 2014;289:1257–70.
 8. Bergeron D, Lapointe C, Bissonnette C, Tremblay G, Motard J, Roucou X. An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting protein*. *J Biol Chem*. 2013;288:21824–35.
 9. Brunet MA, Jacques J-F, Nassari S, Tyzack GE, McGoldrick P, Zinman L, et al. The FUS gene is dual-coding with both proteins contributing to FUS-mediated toxicity. *EMBO Rep*. 2021;22:e50640.
 10. McLean J, Xiao S, Miyazaki K, Robertson J. A novel peripherin isoform generated by alternative translation is required for normal filament network formation. *J Neurochem*. 2008;104:1663–73.
 11. Sapkota D, Lake AM, Yang W, Yang C, Wesseling H, Guise A, et al. Cell-type-specific profiling of alternative translation identifies regulated protein isoform variation in the mouse brain. *Cell Rep*. 2019;26:594–607.e7.
 12. De Bellis M, Pisani F, Mola MG, Rosito S, Simone L, Buccoliero C, et al. Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. *Glia*. 2017;65:790–803.
 13. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain—implications for Alzheimer disease. *Nat Rev Neurol*. 2015;11:457–70.
 14. Peng W, Acharyar TM, Li B, Liao Y, Mestre H, Hitomi E, et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. *Neurobiol Dis*. 2016;93:215–25.
 15. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β . *Sci Transl Med*. 2012;4:147ra111.
 16. Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain A β accumulation and memory deficits. *Mol Neurodegener*. 2015;10:58.
 17. Zeppenfeld DM, Simon M, Haswell JD, D'Abreo D, Murchison C, Quinn JF, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. *JAMA Neurol*. 2017;74:91–9.
 18. Arighi A, Arcaro M, Fumagalli GG, Carandini T, Pietroboni AM, Sacchi L, et al. Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation. *Alzheimer's Res Ther*. 2022;14:135.
 19. Sapkota D, Florian C, Doherty BM, White KM, Reardon KM, Ge X, et al. Aqp4 stop codon readthrough facilitates amyloid- β clearance from the brain. *Brain*. 2022;145:2982–90.
 20. Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: progress and prospects. *Sig Transduct Target Ther*. 2023;8:1–23.
 21. Twohig D, Nielsen HM. α -synuclein in the pathophysiology of Alzheimer's disease. *Mol Neurodegener*. 2019;14:23.
 22. Cui H, Wang W, Zheng X, Xia D, Liu H, Qin C, et al. Decreased AQP4 expression aggravates α -synuclein pathology in Parkinson's disease mice, possibly via impaired glymphatic clearance. *J Mol Neurosci*. 2021;71:2500–13.
 23. Zhang Y, Zhang C, He X-Z, Li Z-H, Meng J-C, Mao R-T, et al. Interaction between the glymphatic system and α -synuclein in Parkinson's disease. *Mol Neurobiol*. 2023;60:2209–22.
 24. Pereira JB, Janelidze S, Strandberg O, Whelan CD, Zetterberg H, Blennow K, et al. Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. *Nat Aging*. 2022;2:1138–44.
 25. Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. *Nat Rev Neurosci*. 2018;19:622–35.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

